Corrigendum

Corrigendum to “A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study”

Naveen T. Krishnareddy ¹, **Justin V. Thomas**,² **Saritha S. Nair**,³ **Johannah N. Mulakal**,³ **Balu P. Maliakel**,³ and **I. M. Krishnakumar** ³

¹Life Care Hospital, Bangalore, India

²Leads Clinical Research & Bio Services Pvt. Ltd., Bangalore, India

³R&D Centre, Akay Flavours & Aromatics Ltd., Kerala, India

Correspondence should be addressed to Naveen T. Krishnareddy; ntklifecare@gmail.com

Received 9 January 2019; Accepted 28 January 2019; Published 3 March 2019

Copyright © 2019 Naveen T. Krishnareddy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study” [1], the dosage of drugs in the Materials and Methods and Results was given incorrectly as (250 mg x 1)/ day. It should be corrected to (250 mg x 2)/ day.

References

- [1] N. T. Krishnareddy, J. V. Thomas, S. S. Nair, J. N. Mulakal, B. P. Maliakel, and I. M. Krishnakumar, “A novel curcumin-galactomannoside complex delivery system improves hepatic function markers in chronic alcoholics: A double-blinded, randomized, placebo-controlled study,” *BioMed Research International*, vol. 2018, Article ID 9159281, 10 pages, 2018.